keyhole limpet hemocyanin
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01489956 | Dec 2011 → Apr 2013 | autoimmune disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 15 trials · 1 missed | ||||||
| Phase 1 | NCT04079062 | Sep 2019 → May 2021 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02947854 | Sep 2016 → Mar 2018 | — | PCI Biotech AS | Completed | No outcome recorded |
| Phase 1 | NCT00614731 | Dec 2007 → Dec 2008 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00003819 | Jun 1998 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00026624 | ? → Oct 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT00282308 | Jan 2006 → Jan 2008 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00019097 | Jul 1995 → Mar 2007 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02545868 | Oct 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT00003638 | Jan 1999 → Jan 2007 | breast cancer | Oncothyreon Canada Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00006034 | Jun 1998 → Mar 2004 | urinary bladder cancer | Intracel | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00536120 | Jan 2008 → Nov 2009 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00005000 | Dec 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01509391 | Jan → Oct 2012 | chronic hepatitis C virus infection, cirrhosis of liver | Medical University of Graz | Completed | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1 | NCT05845996 Background | Nov 2018 → Apr 2020 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02079480 Background | May 2014 → Apr 2016 | — | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT00091143 Background | Jul 2004 → Mar 2010 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02754362 Background | Nov 2016 → Jun 2019 | glioblastoma | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT00093522 Background | Aug 2004 → ? | kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00006478 Background | Oct 2000 → Apr 2008 | lymphoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 2 | NCT00004198 Background | Jun 1999 → Jan 2002 | lymphoma | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00004197 Background | Jun 1999 → Jan 2002 | lymphoma | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00004249 Background | Aug 1998 → Nov 2001 | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00017290 Background | Nov 2000 → ? | lymphoma | Genitope Corporation | Unknown | Missed primary |
| Phase 3 | NCT00091676 Comparator | Jan 2000 → Dec 2012 | non-Hodgkin lymphoma | Biovest International | Unknown | Mixed |
| — | NCT05876195 Comparator | Mar → Oct 2023 | — | University of Oxford | Unknown | No outcome recorded |
| — | NCT00050921 Background | ? → Mar 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | keyhole limpet hemocyanin | “to investigate dosing condition of Keyhole limpet hemocyanin (KLH) and to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity when ONO-4685...” NCT04079062 ↗25“All received tetanus toxoid (TT)-containing vaccine, Pneumovax (23-valent pneumococcal polysaccharide vaccine [23-PPV]), and keyhole limpet hemocyanin (KLH).” PMID 32727835 ↗ Jul 2020 “Each subject received 3 doses of HPV16 E7 peptide antigens and two doses of Keyhole Limpet Hemocyanin (KLH) protein.” PMID 33488576 ↗ Jan 2021 “Keyhole limpet hemocyanin (KLH) is a protein that can be used to deliver vaccines to the body.” NCT00614731 ↗ “keyhole limpet hemocyanin (KLH)” PMID 21632504 ↗ May 2011 |
| Known as | BCI-ImmuneActivator | “Compare the efficacy of BCI-ImmuneActivator™ (keyhole limpet hemocyanin) versus doxorubicin in BCG refractory or intolerant patients with carcinoma in situ with or without...” NCT00006034 ↗ |
| Known as | immunocyanin | “immunocyanin (keyhole-limpet hemocyanin)” NCT00050921 ↗ |
| Known as | Keyhole Limpet Hemocyanin (KLH) | “In this study, oral tolerance of Keyhole Limpet Hemocyanin (KLH) will be tested.” NCT01489956 ↗ |
| Known as | KLH | “Arm II: Patients receive the control treatment of intravenous cyclophosphamide on day -3, followed by 4 subcutaneous vaccinations with keyhole limpet hemocyanin (KLH) vaccine...” NCT00003638 ↗10“A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to...” NCT00091143 ↗ “Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally at week -2 followed by induction KLH IV once weekly at weeks 1-6.” NCT00006034 ↗ “autologous DCs infected with CP-HIV+keyhole limpet hemocyanin (KLH) (arm A, n=14) or CP-HIV+KLH alone (arm B, n=15)” PMID 19450647 ↗ May 2009 “Keyhole limpet hemocyanin (KLH) is a protein that can be used to deliver vaccines to the body.” NCT00614731 ↗ “Keyhole limpet hemocyanin (KLH)” NCT02754362 ↗ “keyhole limpet hemocyanin (KLH)” NCT00536120 ↗ |
| Known as | native KLH | “The 'native KLH' (which is a large version of this protein) formulation will be used for oral feeding.” NCT01489956 ↗ |
| Modality | Vaccine | “keyhole limpet hemocyanin (KLH) vaccine” NCT00003638 ↗ |
| Route | Subcutaneous | “4 subcutaneous vaccinations with keyhole limpet hemocyanin (KLH) vaccine combined with Detox-B Stable Emulsion” NCT00003638 ↗ |